Corbus Pharmaceuticals Holdings, Inc.
NASDAQ: CRBP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yuval Cohen
- Employees
- 36
- Headquarters
- Norwood, United States
- IPO year
- 2014
- Market cap
- $102.5M
- Website
- https://www.corbuspharma.com
Loading CRBP…
Loading profile data…Frequently asked questions about CRBP
What does Corbus Pharmaceuticals Holdings, Inc. (CRBP) do?
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal...
Where does CRBP trade?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) trades on the NASDAQ.
What sector is CRBP in?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Corbus Pharmaceuticals Holdings, Inc.?
Yuval Cohen is the chief executive officer of Corbus Pharmaceuticals Holdings, Inc. (CRBP).
Where is Corbus Pharmaceuticals Holdings, Inc. headquartered?
Corbus Pharmaceuticals Holdings, Inc. is headquartered in United States.
Does CRBP pay a dividend?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CRBP go public?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) completed its initial public offering in 2014.